

JosÃ© M Zijlstra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7695570/publications.pdf>

Version: 2024-02-01

97
papers

5,530
citations

172457

29
h-index

85541

71
g-index

100
all docs

100
docs citations

100
times ranked

7132
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?. Journal of Nuclear Medicine, 2022, 63, 389-395.	5.0	16
2	18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 932-942.	6.4	62
3	A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies. Journal of Nuclear Medicine, 2022, 63, 172-179.	5.0	96
4	¹⁸ F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study. Journal of Nuclear Medicine, 2022, 63, 1001-1007.	5.0	12
5	The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in ¹⁸ F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. Journal of Nuclear Medicine, 2022, 63, 1424-1430.	5.0	20
6	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. Cancers, 2022, 14, 791.	3.7	2
7	3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body 18F-Fluorodeoxyglucose and 89Zr-Rituximab PET Scans. Diagnostics, 2022, 12, 596.	2.6	1
8	Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma. Cancers, 2022, 14, 1346.	3.7	1
9	Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989â€”2018. Blood Cancer Journal, 2022, 12, 38.	6.2	6
10	Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. Journal of Clinical Oncology, 2022, 40, 2352-2360.	1.6	53
11	Bloodâ€™circulating EVâ€™miRNAs, serum TARC, and quantitative FDGâ€™PET features in classical Hodgkin lymphoma. EJHaem, 2022, 3, 908-912.	1.0	2
12	Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs: A randomized controlled trial. Lancet Regional Health - Europe, The, 2022, 18, 100390.	5.6	9
13	Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment. HemaSphere, 2022, 6, e749.	2.7	0
14	Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica, 2021, 106, 1129-1137.	3.5	57
15	Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989â€”2017. Leukemia, 2021, 35, 494-505.	7.2	11
16	Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia, 2021, 35, 143-155.	7.2	52
17	Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. Journal of Nuclear Medicine, 2021, 62, 332-337.	5.0	53
18	PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 223-234.	10.7	93

#	ARTICLE	IF	CITATIONS
19	Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial. <i>Neuro-Oncology</i> , 2021, 23, 1315-1326.	1.2	9
20	Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim ¹⁸ F-FDG PET in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1531-1536.	5.0	8
21	Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1655.2-1656.	5.0	3
22	Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	10.1	10
23	The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review. <i>Cancer Imaging</i> , 2021, 21, 36.	2.8	3
24	Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands. <i>Blood Cancer Journal</i> , 2021, 11, 87.	6.2	1
25	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. <i>Blood Advances</i> , 2021, 5, 2375-2384.	5.2	40
26	PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e398-e409.	4.6	28
27	Extracellular vesicle miRNA predict FDGâ€PET status in patients with classical Hodgkin Lymphoma. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12121.	12.2	18
28	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	5
29	Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. <i>Blood Advances</i> , 2021, 5, 2958-2964.	5.2	11
30	Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example. <i>EJNMMI Research</i> , 2021, 11, 74.	2.5	6
31	Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1.	6.4	4
32	The eHealth self-management application â€Oncokompasâ€ that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most?. <i>Acta OncolÃ³gica</i> , 2021, 60, 403-411.	1.8	34
33	Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 760-769.	6.3	45
34	In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkinâ€™s lymphoma and facilitates ultrasensitive residual disease detection. <i>Med</i> , 2021, 2, 1171-1193.e11.	4.4	24
35	Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data. <i>Blood</i> , 2021, 138, 879-879.	1.4	3
36	High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial. <i>Blood</i> , 2021, 138, 1414-1414.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of shortening treatment duration based on interim PET outcome in patients with diffuse large B-cell lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	0
38	Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 80-94.	10.7	121
39	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256.	1.6	73
40	Self-Reported Sexual Function in Sexually Active Male Hodgkin Lymphoma Survivors. <i>Sexual Medicine</i> , 2020, 8, 428-435.	1.6	9
41	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e511-e522.	4.6	201
42	Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma. <i>Molecular Imaging and Biology</i> , 2020, 22, 1102-1110.	2.6	32
43	Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. <i>Haematologica</i> , 2020, 105, 2805-2812.	3.5	30
44	18f-FDG PET/CT Baseline Radiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2020, 136, 27-28.	1.4	1
45	Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. <i>Blood</i> , 2020, 136, 34-35.	1.4	0
46	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
47	Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 65-79.	6.4	55
48	Efficacy and cost-utility of the eHealth application "Oncokompas"™, supporting patients with incurable cancer in finding optimal palliative care, tailored to their quality of life and personal preferences: a study protocol of a randomized controlled trial. <i>BMC Palliative Care</i> , 2019, 18, 85.	1.8	13
49	Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 2835-2845.	1.6	151
50	Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1840-1849.	6.4	11
51	⁸⁹ Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1825-1832.	5.0	38
52	Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer. <i>Cancer Medicine</i> , 2019, 8, 190-199.	2.8	5
53	Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2019, 20, 216-228.	10.7	163
54	Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRAVE study. <i>Haematologica</i> , 2019, 104, e151-e153.	3.5	27

#	ARTICLE	IF	CITATIONS
55	Updating PET/CT performance standards and PET/CT interpretation criteria should go hand in hand. EJNMMI Research, 2019, 9, 95.	2.5	7
56	Quantitative implications of the updated EARL 2019 PETâ€“CT performance standards. EJNMMI Physics, 2019, 6, 28.	2.7	37
57	Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.. Journal of Clinical Oncology, 2019, 37, 7507-7507.	1.6	3
58	Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial. Blood, 2019, 134, 1547-1547.	1.4	10
59	Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?. Journal of Nuclear Medicine, 2018, 59, 1167-1169.	5.0	32
60	Baseline PET as prognostic marker for Hodgkin?. Blood, 2018, 131, 3-4.	1.4	3
61	Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images. Molecular Imaging and Biology, 2018, 20, 1025-1034.	2.6	13
62	Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. Journal of Clinical Oncology, 2018, 36, 2603-2611.	1.6	7
63	Rationale and design of a cohort study on primary ovarian insufficiency in female survivors of Hodgkinâ€™s lymphoma: influence on long-term adverse effects (SOPHIA). BMJ Open, 2018, 8, e018120.	1.9	3
64	Successful Treatment of MYC rearrangement Positive Large B Cell Lymphoma Patients with R-CHOP21 Plus Lenalidomide: Results of a Multicenter Phase II HOVON Trial. Blood, 2018, 132, 786-786.	1.4	8
65	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. Blood, 2018, 132, 998-998.	1.4	19
66	PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group. Blood, 2018, 132, 925-925.	1.4	12
67	Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. Blood, 2018, 132, 1677-1677.	1.4	2
68	Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. British Journal of Cancer, 2017, 117, 306-314.	6.4	26
69	PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, The, 2017, 390, 2790-2802.	13.7	274
70	Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure. International Journal of Radiation Oncology Biology Physics, 2017, 99, 843-853.	0.8	36
71	Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. PLoS ONE, 2017, 12, e0169828.	2.5	50
72	Reducedâ€“Intensity Chemotherapy in Patients With Advancedâ€“Stage Hodgkin Lymphoma. HemaSphere, 2017, 1, e5.	2.7	18

#	ARTICLE	IF	CITATIONS
73	Long-term survival of gastrointestinal cancer diagnosed in Hodgkin lymphoma survivors.. Journal of Clinical Oncology, 2017, 35, 40-40.	1.6	0
74	PET-CT: reliable cornerstone for Hodgkin lymphoma treatment?. Blood, 2016, 127, 1521-1522.	1.4	3
75	FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?. Haematologica, 2016, 101, 1279-1283.	3.5	14
76	18F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma. EJNMMI Research, 2016, 6, 46.	2.5	8
77	Communication during haematological consultations; patientsâ€™ preferences and professionalsâ€™ performances. Annals of Hematology, 2016, 95, 1177-1183.	1.8	3
78	Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients. JCI Insight, 2016, 1, e89631.	5.0	121
79	Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial.. Journal of Clinical Oncology, 2016, 34, 7500-7500.	1.6	13
80	Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.. Journal of Clinical Oncology, 2016, 34, 7504-7504.	1.6	17
81	An Integrated Process and Outcome Evaluation of a Web-Based Communication Tool for Patients With Malignant Lymphoma: Randomized Controlled Trial. Journal of Medical Internet Research, 2016, 18, e206.	4.3	26
82	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet, The, 2015, 385, 1418-1427.	13.7	154
83	¹⁸ F-FDG or ³ -Deoxy- ¹⁸ F-Fluorothymidine to Detect Transformation of Follicular Lymphoma. Journal of Nuclear Medicine, 2015, 56, 216-221.	5.0	24
84	FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 328-354.	6.4	2,188
85	Active Patient Participation in the Development of an Online Intervention. JMIR Research Protocols, 2014, 3, e59.	1.0	40
86	Immunologic Recovery Following Consolidation with 90Yttrium Ibritumomab Tiuxetan (Zevalin®)-BEAM and Autologous Stem Cell Transplantation for Transformed B Cell Non-Hodgkinâ€™s Lymphoma. Blood, 2014, 124, 5882-5882.	1.4	0
87	Barriers and facilitators to effective communication experienced by patients with malignant lymphoma at all stages after diagnosis. Psycho-Oncology, 2013, 22, 2807-2814.	2.3	38
88	First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy. Blood, 2012, 120, 57-57.	1.4	5
89	90Yttrium Ibritumomab Tiuxetan-BEAM Followed by Autologous Stem Cell Transplantation Significantly Improves Overall Survival After Rituximab Containing Induction Therapy in Patients with High-Risk Aggressive B Cell Non-Hodgkin's Lymphoma. Blood, 2011, 118, 3078-3078.	1.4	1
90	First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,. Blood, 2011, 118, 4110-4110.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Does 18F-Fluorodeoxyglucose Outperform 18F-Fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin's Lymphoma,. Blood, 2011, 118, 3658-3658.	1.4	0
92	Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial. Blood, 2010, 116, 764-764.	1.4	11
93	Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood, 2010, 116, 765-765.	1.4	14
94	Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments. Leukemia and Lymphoma, 2009, 50, 1748-1749.	1.3	18
95	The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2320-2333.	6.4	343
96	18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica, 2006, 91, 522-9.	3.5	155
97	18 FDG positron emission tomography versus 67 Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. British Journal of Haematology, 2003, 123, 454-462.	2.5	37